Unknown

Dataset Information

0

Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus.


ABSTRACT: The Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated in 2012, and circulated worldwide with high mortality. The continual outbreaks of MERS-CoV highlight the importance of developing antiviral therapeutics. Here, we rationally designed a novel fusion inhibitor named MERS-five-helix bundle (MERS-5HB) derived from the six-helix bundle (MERS-6HB) which was formed by the process of membrane fusion. MERS-5HB consists of three copies of heptad repeat 1 (HR1) and two copies of heptad repeat 2 (HR2) while MERS-6HB includes three copies each of HR1 and HR2. As it lacks one HR2, MERS-5HB was expected to interact with viral HR2 to interrupt the fusion step. What we found was that MERS-5HB could bind to HR2P, a peptide derived from HR2, with a strong affinity value (KD) of up to 0.24 nM. Subsequent assays indicated that MERS-5HB could inhibit pseudotyped MERS-CoV entry effectively with 50% inhibitory concentration (IC50) of about 1 ?M. In addition, MERS-5HB significantly inhibited spike (S) glycoprotein-mediated syncytial formation in a dose-dependent manner. Further biophysical characterization showed that MERS-5HB was a thermo-stable ?-helical secondary structure. The inhibitory potency of MERS-5HB may provide an attractive basis for identification of a novel inhibitor against MERS-CoV, as a potential antiviral agent.

SUBMITTER: Sun Y 

PROVIDER: S-EPMC5618021 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus.

Sun Yaping Y   Zhang Huaidong H   Shi Jian J   Zhang Zhe Z   Gong Rui R  

Viruses 20170914 9


The Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated in 2012, and circulated worldwide with high mortality. The continual outbreaks of MERS-CoV highlight the importance of developing antiviral therapeutics. Here, we rationally designed a novel fusion inhibitor named MERS-five-helix bundle (MERS-5HB) derived from the six-helix bundle (MERS-6HB) which was formed by the process of membrane fusion. MERS-5HB consists of three copies of heptad repeat 1 (HR1) and two copies of  ...[more]

Similar Datasets

2014-06-10 | GSE56189 | GEO
2014-06-10 | GSE56192 | GEO
| S-EPMC6567157 | biostudies-literature
2014-06-10 | E-GEOD-55023 | biostudies-arrayexpress
2015-11-19 | E-GEOD-56193 | biostudies-arrayexpress
| S-EPMC4786625 | biostudies-other
| S-EPMC6986839 | biostudies-literature
| S-EPMC7091805 | biostudies-literature
| S-EPMC7169231 | biostudies-literature
| PRJNA376858 | ENA